drugset / Trial / NCT05250050
Susceptibility-Guided Therapy for Helicobacter Pylori Infection Treatment
RandomizedParallel-groupSingle-blindTreatment
Summary
This multicenter randomized controlled clinical trial was conducted to compare the eradication efficacy and health economic benefits of individualized regimens based on HP drug resistance mutation gene detection (multiple PCR method), individualized regimens based on HP traditional drug sensitivity testing (E-test method) and empirical regimens in the Helicobacter pylori treatment.
Timeline
- Start
- 2022-03-25
- Primary completion
- 2022-12-30
- Completion
- 2023-03-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Amoxicillin | Other / unclassified | 1 g | — |
| Subject | Clarithromycin | Small molecule | 0.5 g | — |
| Subject | Levofloxacin | Small molecule | 0.5 g | — |
| Subject | Metronidazole | Small molecule | 0.4 g | — |
| Subject | Tetracycline | Unknown | 0.5 g | — |
| Background | Bismuth Potassium Citrate | Unknown | 0.6 g | — |
| Background | Esomeprazole | Small molecule | 20 mg | — |